背景:Evo二胺(EVO)是吴茱萸的主要成分之一,已发现对各种消化系统疾病具有积极的治疗作用。然而,关于EVO与消化系统疾病相关的研究进展和机制尚未进行系统评价,和它的毒性。
目的:本研究旨在为今后该领域的研究提供参考。
方法:对研究进展进行系统综述和荟萃分析,机制,EVO治疗消化系统疾病的毒性。
方法:利用五个电子数据库搜索相关实验。我们遵循系统评价和荟萃分析(PRISMA)的首选报告项目指南,对相关文献进行了全面审查和荟萃分析。
结果:EVO在消化系统疾病中的动物实验主要集中在结直肠癌,胃溃疡,肝癌,肝纤维化,溃疡性结肠炎,结肠炎相关的癌症,和功能性胃肠病。EVO对胰腺癌也有积极作用,放射性肠炎,胃癌,舌鳞癌,乙型肝炎,口腔癌,和体内食道癌。细胞实验中的EVO主要集中在SGC7901、HT29、HCT-116和HepG2细胞上。EVO还对SW480、LoVo、BGC-823,AGS,体外COLO-205、MKN45、SMMC-7721、Bel-7402、QGY7-701、PANC-1、SW1990、BxPC-3、HSC4、MC3、HONE1和CNE1细胞。潜在的共同途径包括TGF-β,PI3K-AKT,Wnt,ErbB,mTOR,MAPK,HIF-1,NOD样受体,NF-κB,VEGF,JAK-STAT,AMPK,Toll样受体,EGFR,拉斯,TNF,年龄-愤怒,放松素,福克斯,IL-17河马,和cAMP。EVO对溃疡性结肠炎的作用机制,胃癌,和HCT116细胞在体内仍有争议。EVO可能通过钙信号传导对功能性胃肠病具有双向调节作用。EVO对HCT116、HT29、SW480、AGS、COLO-205和SW1990细胞在体外仍然存在争议。EVO是否具有明显的毒性是有争议的。
结论:在细胞和动物实验中,EVO对消化系统疾病具有积极影响。然而,需要进一步的体内和体外研究来确认EVO对消化系统疾病的有益作用和机制,以及其潜在的毒性。
BACKGROUND: Evodiamine (EVO) is one of the primary components of Evodia rutaecarpa and has been found to have a positive therapeutic effect on various digestive system diseases. However, no systematic review has been conducted on the research progress and mechanisms of EVO in relation to digestive system diseases, and its toxicity.
OBJECTIVE: This study aimed to provide a reference for future research in this field.
METHODS: A systematic review and meta-analysis of the research progress, mechanisms, and toxicity of EVO in the treatment of digestive system diseases.
METHODS: Five electronic databases were utilized to search for relevant experiments. We conducted a comprehensive review and meta-analysis of the pertinent literature following the guidelines of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA).
RESULTS: EVO\'s animal experiments in digestive system diseases primarily focus on colorectal cancer, gastric ulcers, liver cancer, liver fibrosis, ulcerative colitis, colitis-associated cancer, and functional gastrointestinal disorders. EVO also has positive effects on pancreatic cancer, radiation enteritis, gastric cancer, tongue squamous cancer, hepatitis B, oral cancer, and esophageal cancer in vivo. EVO\'s in cellular experiments primarily focus on SGC7901, HT29, HCT-116, and HepG2 cells. EVO also exhibits positive effects on SW480, LoVo, BGC-823, AGS, COLO-205, MKN45, SMMC-7721, Bel-7402, QGY7-701, PANC-1, SW1990, BxPC-3, HSC4, MC3, HONE1, and CNE1 cells in vitro. The potential common pathways include TGF-β, PI3K-AKT, Wnt, ErbB, mTOR, MAPK, HIF-1, NOD-like receptor, NF-κB, VEGF, JAK-STAT, AMPK, Toll-like receptor, EGFR, Ras, TNF, AGE-RAGE, Relaxin, FoxO, IL-17, Hippo, and cAMP. The mechanisms of EVO on ulcerative colitis, gastric cancer, and HCT116 cells are still controversial in vivo. EVO may have a bidirectional regulatory effect on functional gastrointestinal disorders through calcium signaling. The mechanisms of EVO on HCT116, HT29, SW480, AGS, COLO-205, and SW1990 cells are still controversial in vitro. The question of whether EVO has obvious toxicity is controversial.
CONCLUSIONS: In both cellular and animal experiments, EVO has demonstrated positive impacts on digestive system diseases. Nevertheless, additional in vivo and in vitro research is required to confirm the beneficial effects and mechanisms of EVO on digestive system diseases, as well as its potential toxicity.